Usual Care for Clinicians, Unusual Care for Their Clients: Rearranging Priorities for Children’s Mental Health Services

M. Atkins,Davielle Lakind

DOI: https://doi.org/10.1007/s10488-012-0453-5

Administration and Policy in Mental Health and Mental Health Services Research

Abstract:

What problem does this paper attempt to address?

Recent progress on functional cure for acquired immunodeficiency syndrome

Jia Sun,Biao Zhu

DOI: https://doi.org/10.3760.cma.j.issn.1673-4149.2014.04.013

2014-01-01

Abstract:Acquired immunodeficiency syndrome caused by HIV has been considered as one of the worldwide incurable illnesses.Despite the huge clinical success of HAART,several factors such as adverse effects,requirement of life-long adherence,high cost,and drug resistance make the request for an ultimate cure of HIV/ AIDS.The functional cure is the achievement of spontaneous drug-free control of HIV infection without disease progression.The review summarizes the main achievements in protecting HIV target cells—CD4+ T cells,CLT immune enhancement,depletion of latent reservoir,hematopoietic stem cell transplantation and gene therapy.
Navigating the Roadblocks: Progress and Challenges in Cell‐Based Therapies for Human Immunodeficiency Virus

Lakshay Chhabra,Rajeev Kumar Pandey,Rajiv Kumar,Shyam Sundar,Sanjana Mehrotra

DOI: https://doi.org/10.1002/jcb.30669

2024-11-03

Journal of Cellular Biochemistry

Abstract:Cell‐based therapies represent a major advancement in the treatment and management of HIV/AIDS, with a goal to overcome the limitations of traditional antiretroviral therapy (ART). These innovative approaches not only promise a functional cure by reconstructing the immune landscape but also address the persistent viral reservoirs. For example, stem cell therapies have emerged from the foundational success of allogeneic hematopoietic stem cell transplantation in curing HIV infection in a limited number of cases. B cell therapies make use of genetically modified B cells constitutively expressing broadly neutralizing antibodies (bNAbs) against target viral particles and infected cells. Adoptive cell transfer (ACT), including TCR‐T therapy, CAR‐T cells, NK‐CAR cells, and DC‐based therapy, is adapted from cancer immunotherapy and repurposed for HIV eradication. In this review, we summarize the mechanisms through which these engineered cells recognize and destroy HIV‐infected cells, the modification strategies, and their role in sustaining remission in the absence of ART. The review also addresses the challenges to cell‐based therapies against HIV and discusses the recent advancements aimed at overcoming them.

cell biology,biochemistry & molecular biology
Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies

Aditi Chatterjee,Aerielle Matsangos,Olga S Latinovic,Alonso Heredia,Giovannino Silvestri

DOI: https://doi.org/10.46439/stemcell.5.020

Abstract:Human immunodeficiency virus type 1 (HIV-1) continues to pose a significant global health challenge despite advances in combined antiretroviral therapy (cART), which has transformed HIV-1 infection from a fatal disease to a manageable chronic condition. However, cART is not curative, and its long-term use is associated with challenges such as pill burden, drug toxicities, and the emergence of drug-resistant viral strains. The persistence of active viral reservoirs necessitates lifelong treatment, highlighting the need for alternative therapeutic strategies capable of achieving HIV-1 remission or cure. Stem cell therapy has emerged as a promising approach to address these challenges by targeting latent viral reservoirs, restoring host immune function, and potentially achieving sustained viral suppression in the absence of cART. This review critically evaluates current scientific literature on stem cell therapies for HIV-1, focusing on three major approaches: 1) hematopoietic stem cell transplantation (HSCT), 2) gene therapy, and 3) cell-based immunotherapies. Each approach is examined in terms of its underlying mechanisms, clinical feasibility, recent advancements, and associated challenges. Furthermore, future research directions are discussed, emphasizing the optimization of the current treatment protocols, enhancement of safety and efficacy, and the importance of large-scale clinical trials with different cohorts (different HIV clades, different genders of participants, and pediatric HIV) to evaluate long-term outcomes that include effective and scalable HIV cure challenges. Collaborative efforts across multidisciplinary fields are needed to overcome existing barriers so to realize the full therapeutic potential of stem cell-based approaches for developing an effective and scalable remission or cure strategies.
Advanced Therapies for Human Immunodeficiency Virus

Daniel Josef Lindegger

DOI: https://doi.org/10.3390/medsci12030033

2024-07-18

Abstract:Human Immunodeficiency Virus (HIV) remains a significant global health challenge with approximately 38 million people currently having the virus worldwide. Despite advances in treatment development, the virus persists in the human population and still leads to new infections. The virus has a powerful ability to mutate and hide from the human immune system in reservoirs of the body. Current standard treatment with antiretroviral therapy effectively controls viral replication but requires lifelong adherence and does not eradicate the virus. This review explores the potential of Advanced Therapy Medicinal Products as novel therapeutic approaches to HIV, including cell therapy, immunisation strategies and gene therapy. Cell therapy, particularly chimeric antigen receptor T cell therapy, shows promise in preclinical studies for targeting and eliminating HIV-infected cells. Immunisation therapies, such as broadly neutralising antibodies are being investigated to control viral replication and reduce reservoirs. Despite setbacks in recent trials, vaccines remain a promising avenue for HIV therapy development. Gene therapy using technologies like CRISPR/Cas9 aims to modify cells to resist HIV infection or eliminate infected cells. Challenges such as off-target effects, delivery efficiency and ethical considerations persist in gene therapy for HIV. Future directions require further research to assess the safety and efficacy of emerging therapies in clinical trials. Combined approaches may be necessary to achieve complete elimination of the HIV reservoir. Overall, advanced therapies offer new hope for advancing HIV treatment and moving closer to a cure.
Gaining momentum: stem cell therapies for HIV cure

Amanda M. Buck,Brian H. LaFranchi,Timothy J. Henrich

DOI: https://doi.org/10.1097/coh.0000000000000859

2024-04-26

Current Opinion in HIV and AIDS

Abstract:Purpose of review Durable HIV-1 remission has been reported in a person who received allogeneic stem cell transplants (SCTs) involving CCR5 Δ32/Δ32 donor cells. Much of the reduction in HIV-1 burden following allogeneic SCT with or without donor cells inherently resistant to HIV-1 infection is likely due to cytotoxic graft-versus-host effects on residual recipient immune cells. Nonetheless, there has been growing momentum to develop and implement stem cell therapies that lead to durable long-term antiretroviral therapy (ART)-free remission without the need for SCT. Recent findings Most current research leverages gene editing techniques to modify hematopoietic stem cells which differentiate into immune cells capable of harboring HIV-1. Approaches include targeting genes that encode HIV-1 co-receptors using Zinc Finger Nucleases (ZFN) or CRISPR-Cas-9 to render a pool of adult or progenitor cells resistant to de-novo infection. Other strategies involve harnessing multipotent mesenchymal stromal cells to foster immune environments that can more efficiently recognize and target HIV-1 while promoting tissue homeostasis. Summary Many of these strategies are currently in a state of infancy or adolescence; nonetheless, promising preclinical and first-in-human studies have been performed, providing further rationale to focus resources on stem cell therapies.

immunology,infectious diseases
Current Status and Future Development of Anti-Hiv Chimeric Antigen Receptor T-cell Therapy

Yunyu Mao,Chen Zhao,Peiyong Zheng,Xiaoyan Zhang,Jianqing Xu

DOI: https://doi.org/10.2217/imt-2020-0199

2021-01-01

Immunotherapy

Abstract:Despite the success of antiretroviral therapy in suppressing HIV to an undetectable level in the blood and improving patients' quality of life, HIV persists in antiretroviral therapy-treated patients and threatens their lives. Anti-HIV chimeric antigen receptor (CAR) T cells could offer a cure by recognizing and killing virus-producing cells in an Env-specific manner. In this review, the authors summarize several important aspects of the development of anti-HIV CAR T cells, with a special focus on the evolution of CAR design for enhanced potency and targeting specificity, and also outline the challenges that still need to be addressed to take anti-HIV CAR T cells from a hopeful approach to a real HIV cure.
Strategies for HIV-1 suppression through key genes and cell therapy

Alyona Sorokina,Elizaveta Anchakova,Erdem Dashinimaev

DOI: https://doi.org/10.3389/fmed.2023.1259995

2023-11-29

Abstract:Human immunodeficiency virus type 1 (HIV-1) remains a significant challenge for global public health as limited therapeutic options are available for HIV-infected individuals receiving combination antiretroviral therapy. Additionally, individuals with HIV-1/acquired immunodeficiency syndrome (AIDS) complications have a reduced life expectancy. In recent decades, gene and cell-based strategies have shown promise in achieving a functional cure for HIV-1 infection. The outcomes of therapies with patients in Berlin and London have led to moderate optimism for a highly effective HIV-1 treatment. This review categorizes current strategies for HIV-1 treatment into RNA- and antibody-based therapies, cell and genome editing approaches, and methods for eradicating latent reservoirs. These findings demonstrate how the use of various anti-HIV-1 agents enhances our understanding of HIV-1 infection and may provide important insights for potential HIV-1 treatment.
Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

Wei Xu,Haoyang Li,Qian Wang,Chen Hua,Hanzhen Zhang,Weihua Li,Shibo Jiang,Lu

DOI: https://doi.org/10.1155/2017/6096134

2017-01-01

BioMed Research International

Abstract:Combined antiretroviral therapy (cART) has been successful in prolonging lifespan and reducing mortality of patients infected with human immunodeficiency virus (HIV). However, the eradication of latent HIV reservoirs remains a challenge for curing HIV infection (HIV cure) because of HIV latency in primary memory CD4+ T cells. Currently, two types of HIV cures are in development: a “sterilizing cure” and a “functional cure.” A sterilizing cure refers to the complete elimination of replication-competent proviruses in the body, while a functional cure refers to the long-term control of HIV replication without treatment. Based on these concepts, significant progress has been made in different areas. This review focuses on recent advancements and future prospects for HIV cures.
CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges

Wang Xiao,Liu Jianyang,Hao Feike,Ajavavarakula Tatchapon,Shi Xuanling

DOI: https://doi.org/10.1097/id9.0000000000000129

2024-01-01

Infectious Diseases & Immunity

Abstract:Chimeric antigen receptor T (CAR-T) cell therapy, renowned for its successes in cancer treatment, is now entering the field of human immunodeficiency virus (HIV) therapy, presenting both opportunities and challenges. With the emergence of broadly neutralizing antibodies, multi-target CARs, and T cell receptor-like antibodies aimed at increasing specificity in targeting HIV reservoirs, CAR-T therapy is synergizing with other cutting-edge treatments, including gene-editing technologies, therapeutic vaccines, and latency-reversing agents, in pursuit of a potential functional cure. In this review, we delve into the role of CAR-T therapy in HIV treatment, highlighting its potential to overcome clinical obstacles. We discuss advancements in targeting strategies within CAR constructs and the intricate regulation of T cell proliferation and chemotaxis. Moreover, we explore the use of diverse immune cells, such as gamma-delta T cells and natural killer cells. We review advanced biotechnologies, manufacturing innovations, viral mechanisms, and immune microenvironments. We also discuss the current research landscape and potential future applications of CAR-T therapy against HIV, which remains a critical global health challenge.
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission

Hang Su,April Mueller,Harris Goldstein

DOI: https://doi.org/10.1097/coh.0000000000000858

2024-06-07

Current Opinion in HIV and AIDS

Abstract:Successful sustained remission of HIV infection has been achieved after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation for treatment of leukemia in a small cohort of people living with HIV (PLWH). This breakthrough demonstrated that the goal of curing HIV was achievable. However, the high morbidity and mortality associated with bone marrow transplantation limits the routine application of this approach and provides a strong rationale for pursuing alternative strategies for sustained long-term antiretroviral therapy (ART)-free HIV remission. Notably, long-term immune-mediated control of HIV replication observed in elite controllers and posttreatment controllers suggests that potent HIV-specific immune responses could provide sustained ART-free remission in PLWH. The capacity of chimeric antigen receptor (CAR)-T cells engineered to target malignant cells to induce remission and cure in cancer patients made this an attractive approach to provide PLWH with a potent HIV-specific immune response. Here, we review the recent advances in the design and application of anti-HIV CAR-T-cell therapy to provide a functional HIV cure.

immunology,infectious diseases
Gene therapy for HIV infection

Carmen de Mendoza,Pablo Barreiro,Laura Benitez,Vicente Soriano

DOI: https://doi.org/10.1517/14712598.2015.967208

Abstract:Introduction: Highly active antiretroviral therapy has been the big paradigm for transforming HIV infection in a chronic disease. However, it requires lifelong administration as the HIV provirus integrated within infected cells cannot be eliminated and virus replication resumes following antiviral discontinuation. Cumulative toxicities, incomplete immune restoration, elevated cost, drug-drug interactions and selection of drug-resistant viruses are well-known limitations of prolonged HIV medication. Areas covered: The first proof-of-concept that HIV infection could be cured was the Berlin patient. By blocking infection of target cells, gene therapy may allow viral clearance from carriers or prevention of infection in newly exposed individuals. Advances in the field of gene-targeting strategies, T-cell-based approaches and human stem cells are revolutionizing the field. A series of ongoing and planned trials are testing gene therapy as HIV cure. The ultimate goal is the elimination of latent viral reservoirs in HIV-infected persons and the need for lifelong antiretroviral therapy. Following a search in PubMed, we have reviewed current gene therapy strategies investigated for HIV infection as well as the latest communications on HIV eradication presented at international conferences. Expert opinion: Multiple efforts are underway to reproduce the Berlin patient situation by engineering autologous T cells or hematopoietic stem cells resistant to HIV infection. There is no doubt that the major challenge is the elimination of latent viral reservoirs. With this goal in mind, we have entered a new era in the hope for HIV cure.
Utilizing immunotherapy towards achieving a functional cure for HIV-1

Fabrícia Heloisa Cavicchioli Sugiyama,Lisa Loksø Dietz,Ole Schmeltz Søgaard

DOI: https://doi.org/10.1097/coh.0000000000000856

2024-04-12

Current Opinion in HIV and AIDS

Abstract:Purpose of review Advancements in antiretroviral therapy (ART) have positively impacted the life expectancy and possibility of living a normal life for people with HIV-1. However, lifelong daily medication is necessary to prevent disease progression. To this end, immunotherapeutic strategies are being tested with the aim of developing a functional cure in which the immune system effectively controls HIV-1 in the absence of ART. Recent findings The most promising advances in achieving sustained HIV-1 remission or cure include broadly neutralizing antibodies (bNAbs) that are administered alone or in combination with other agents. Newer and more innovative approaches redirecting T cells or natural killer cells to kill HIV-1 infected cells have also shown promising results. Finally, multiple ongoing trials focus on combining bNAbs with other immune-directed therapies to enhance both innate and adaptive immunity. Summary While immunotherapies as an alternative to conventional ART have generally proven to be well tolerated, these therapeutic approaches have largely been unsuccessful in inducing ART-free control of HIV-1. However, promising results from recent trials involving bNAbs that have reported durable HIV-1 control among a subset of participants, provide reason for cautious optimism that we with further optimization of these treatment strategies may be able to achieve functional cure for HIV-1.

immunology,infectious diseases
HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

Kouki Matsuda,Kenji Maeda

DOI: https://doi.org/10.3390/ijms25052621

IF: 5.6

2024-02-24

International Journal of Molecular Sciences

Abstract:Combination antiretroviral therapy (cART) has significantly improved the prognosis of individuals living with human immunodeficiency virus (HIV). Acquired immunodeficiency syndrome has transformed from a fatal disease to a treatable chronic infection. Currently, effective and safe anti-HIV drugs are available. Although cART can reduce viral production in the body of the patient to below the detection limit, it cannot eliminate the HIV provirus integrated into the host cell genome; hence, the virus will be produced again after cART discontinuation. Therefore, research into a cure (or remission) for HIV has been widely conducted. In this review, we focus on drug development targeting cells latently infected with HIV and assess the progress including our current studies, particularly in terms of the "Shock and Kill", and "Block and Lock" strategies.

biochemistry & molecular biology,chemistry, multidisciplinary
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

Steven Deeks,Sharon Lewin,Marein de Jong,Zaza Ndhlovu,Nicolas Chomont,Zabrina Brumme,Kai Deng,Luke Jasenosky,Richard Jefferys,Aurelio Orta-Resendiz,Frank Mardarelli,Monique Nijhuis,Katharine Bar,Bonnie Howell,Alex Schneider,Gabriela Turk,Rose Nabatanzi,Joel Blankson,J. Victor Garcia,Mirko Paiardini,Jan van Lunzen,Christina Antoniadi,Fernanda Heloise Côrtes,Susana Valente,Ole S. Søgaard,Ricardo Sobhie Diaz,Melannie Ott,Richard (Rick) Dunham,Siegfried Schwarze,Santiago Perez Patrigeon,Josephine Nabukenya,Marina Caskey,Beatriz Mothe,Fu Sheng Wang,Sarah Fidler,Devi SenGupta,Stephan Dressler,Mitch Matoga,Hans-Peter Kiem,Pablo Tebas,Cissy Kityo,Boro Dropulic,Michael Louella,Kumitaa Theva Das,Deborah Persaud,Ann Chahroudi,Katherine Luzuriaga,Thanyawee Puthanakit,Jeffrey Safrit,Gaerolwe Masheto,Karine Dubé,Jennifer Power,Jessica Salzwedel,Udom Likhitwonnawut,Jeff Taylor,Oguzhan Latif Nuh,Krista Dong,Edward Nelson Kankaka,Steven G. Deeks,Nancie Archin,Paula Cannon,Simon Collins,R. Brad Jones,Marein A. W. P. de Jong,Olivier Lambotte,Rosanne Lamplough,Thumbi Ndung’u,Jeremy Sugarman,Caroline T. Tiemessen,Linos Vandekerckhove,Sharon R. Lewin,Richard Dunham,,,,,,,,,,

DOI: https://doi.org/10.1038/s41591-021-01590-5

IF: 82.9

2021-12-01

Nature Medicine

Abstract:Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cells are not recognized as foreign because they are largely transcriptionally silent, but contain replication-competent virus that drives resurgence of the infection once ART is stopped. With a combination of immune activators, neutralizing antibodies, and therapeutic vaccines, some nonhuman primate models have been cured, providing optimism for these approaches now being evaluated in human clinical trials. In vivo delivery of gene-editing tools to either target the virus, boost immunity or protect cells from infection, also holds promise for future HIV cure strategies. In this Review, we discuss advances related to HIV cure in the last 5 years, highlight remaining knowledge gaps and identify priority areas for research for the next 5 years.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Engineering Hematopoietic Stem Cells Toward a Functional Cure of Human Immunodeficiency Virus Infection

Jianbin Wang,Michael C. Holmes

DOI: https://doi.org/10.1016/j.jcyt.2016.07.007

IF: 6.196

2016-01-01

Cytotherapy

Abstract:The battle with human immunodeficiency virus (HIV) has been ongoing for more than 30 years, and although progress has been made, there are still significant challenges remaining. A few unique features render HIV to be one of the toughest viruses to conquer in the modern medicine era, such as the ability to target the host immune system, persist by integrating into the host genome and adapt to a hostile environment such as a single anti-HIV medication by continuously evolving. The finding of combination anti-retroviral therapy (cART) about 2 decades ago has transformed the treatment options for HIV-infected patients and significantly improved patient outcomes. However, finding an HIV cure has proven to be extremely challenging with the only known exception being the so-called "Berlin patient," whose immune system was replaced by stem cell transplants from a donor missing one of HIV's key co-receptors (CCR5). The broad application of this approach is limited by the requirement of an HLA-matched donor who is also homozygous for the rare CCR5 delta32 deletion. On the other hand, the Berlin patient provided the proof of concept of a potential cure for HIV using HIV-resistant hematopoietic stem cells (HSCs), revitalizing the hope to find an HIV cure that is broadly applicable. Here we will review strategies and recent attempts to engineer HIV-resistant HSCs as a path to an HIV cure.
No t fo r d ist rib uti on 1 Forgetting Preliminary considerations

H. Roediger,Y. Weinstein,P. Agarwal

Abstract:Of all the common afflictions from which humankind suffers, forgetting is probably the most common. Each of us, every day, forgets something we wish we could remember. It might be something we have done, something we intended to do, a fact, a name of a person or restaurant, and so on ad infinitum. As we age, our incidents of forgetting increase and we worry more about them. A whole industry of books, tapes, and even new mental gymnasia has grown up to deal with the cognitive frailties of old age, the primary one being rampant forgetting. Compared to other nuisances of life, forgetting probably tops the list. The “common cold” is actually quite rare compared to forgetting in all its manifestations. As Underwood (1966) wrote: “Forgetting is a most exasperating and sometimes even painful phenomenon” (p. 542). More recently, Nairne and Pandeirada (2008) maintained that for most people “forgetting is a scourge, a nuisance, a breakdown in an otherwise efficient mental capacity” (p. 179), although they quickly noted that there is often an adaptive value in forgetting too. Despite the fact that psychologists have been studying learning and memory for 125 years, the current volume is the only one we can find devoted solely to the topic of forgetting. “Forgetting” is a term used in the titles of many works of fiction and even cultural critique (see Markowitsch & Brand, Chapter 2), but this volume is the first scientific one devoted to it. Strange, you might think. Given the ubiquity of forgetting in our daily lives, the quote by Nietzsche that heads our chapter must seem stranger still. Given its ubiquity, how can the existence of forgetting be doubted? Difficulties of these sorts usually revolve around matters of definition, and that is the case here. We turn to this issue first.
Strategies for human immunodeficiency virus cure：current status and future prospects

Hao-Yang LI,Yu-Chen QU,Qian WANG,Shi-Bo JIANG,Lu LU

2015-01-01

Abstract:The combined antiretroviral therapy (cART ) has been applied to control the course of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) . However , cART requires life‐long daily treatment and strict adherence . HIV can quickly rebound after drug withdrawal because of the presence of the latent HIV reservoir in vivo .Therefore ,reactivation of latent HIV and elimination of latent HIV reservoir are critical for cure of HIV infection and AIDS .Here ,we review the recent advancements and future prospects on the strategies for HIV cure .
Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV

Paul G Rubinstein,Carlos Galvez,Richard F Ambinder

DOI: https://doi.org/10.1097/QCO.0000000000001022

2024-08-01

Abstract:Purpose of review: Summarize the latest research of both stem cell transplantation and cellular therapy and present the implications with respect to persons with HIV (PWH), hematologic malignancies, and HIV-1 cure. Recent findings: Allogeneic (alloSCT) and autologous (autoSCT) stem cell transplantation have been shown to be well tolerated and effective regardless of HIV-1 status. AlloSCT leads to a decrease in the HIV-1 latently infected reservoir orders of magnitude below that achieved with antiretroviral therapy (ART) alone. Utilization of CCR5Δ2/Δ32 donors in an alloSCT has resulted in HIV-1 cures. In the last 12 months, three cases of cure have been published, giving further insight into the conditions required for HIV-1 control. Other advances in the treatment of hematological cancers include chimeric antigen receptor T-cell (CART) therapy, which are active in PWH with lymphoma. Summary: Here we discuss the advances in SCT and cellular therapy in PWH and cancer. Additionally, we discuss how these technologies are being utilized to achieve HIV-1 cure.
HIV cure: Are we going to make history?

Shuvasree Payra,Pramod Kumar Manjhi,Shruti Singh,Rajesh Kumar,Sunil Kumar Singh,Alok Kumar,Vikas Maharshi

DOI: https://doi.org/10.1111/hiv.13557

2023-10-13

HIV Medicine

Abstract:Background At present, combination antiretroviral therapy (cART) is the mainstay for the treatment of people living with HIV/AIDS. cART can suppress the viral load to a minimal level; however, the possibility of the emergence of full‐blown AIDS is always there. In the latter part of the first decade of the 21st century, an HIV‐positive person received stem cell transplantation (SCT) for treatment of his haematological malignancy. The patient was able to achieve remission of the haematological condition as well as of HIV following SCT. Thorough investigations of various samples including blood and biopsy could not detect the virus in the person's body. The person was declared to be the first cured case of HIV. Literature search Over the next decade, a few more similar cases were observed and have recently been declared cured of the infection. A comprehensive search was performed in PubMed, Cochrane library and Google Scholar. Four such additional cases were found in literature. Description & Discussion These cases all share a common proposed mechanism for the HIV cure, that is, transplantation of stem cells from donors carrying a homozygous mutation in a gene encoding for CCR5 (receptor utilized by HIV for entry into the host cell), denoted as CCR5△32. This mutation makes the host immune cells devoid of CCR5, causing the host to acquire resistance against HIV. To the best of our knowledge, this is the first review to look at relevant and updated information of all cured cases of HIV as well as the related landmarks in history and discusses the underlying mechanism(s).

infectious diseases
Altering cell death pathways as an approach to cure HIV infection

A D Badley,A Sainski,F Wightman,S R Lewin

DOI: https://doi.org/10.1038/cddis.2013.248

2013-07-01

Cell Death and Disease

Abstract:Recent cases of successful control of human immunodeficiency virus (HIV) by bone marrow transplant in combination with suppressive antiretroviral therapy (ART) and very early initiation of ART have provided proof of concept that HIV infection might now be cured. Current efforts focusing on gene therapy, boosting HIV-specific immunity, reducing inflammation and activation of latency have all been the subject of recent excellent reviews. We now propose an additional avenue of research towards a cure for HIV: targeting HIV apoptosis regulatory pathways. The central enigma of HIV disease is that HIV infection kills most of the CD4 T cells that it infects, but those cells that are spared subsequently become a latent reservoir for HIV against which current medications are ineffective. We propose that if strategies could be devised which would favor the death of all cells which HIV infects, or if all latently infected cells that release HIV would succumb to viral-induced cytotoxicity, then these approaches combined with effective ART to prevent spreading infection, would together result in a cure for HIV. This premise is supported by observations in other viral systems where the relationship between productive infection, apoptosis resistance, and the development of latency or persistence has been established. Therefore we propose that research focused at understanding the mechanisms by which HIV induces apoptosis of infected cells, and ways that some cells escape the pro-apoptotic effects of productive HIV infection are critical to devising novel and rational approaches to cure HIV infection.

cell biology

Usual Care for Clinicians, Unusual Care for Their Clients: Rearranging Priorities for Children’s Mental Health Services

Recent progress on functional cure for acquired immunodeficiency syndrome

Navigating the Roadblocks: Progress and Challenges in Cell‐Based Therapies for Human Immunodeficiency Virus

Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies

Advanced Therapies for Human Immunodeficiency Virus

Gaining momentum: stem cell therapies for HIV cure

Current Status and Future Development of Anti-Hiv Chimeric Antigen Receptor T-cell Therapy

Strategies for HIV-1 suppression through key genes and cell therapy

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges

Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission

Gene therapy for HIV infection

Utilizing immunotherapy towards achieving a functional cure for HIV-1

HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

Engineering Hematopoietic Stem Cells Toward a Functional Cure of Human Immunodeficiency Virus Infection

No t fo r d ist rib uti on 1 Forgetting Preliminary considerations

Strategies for human immunodeficiency virus cure：current status and future prospects

Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV

HIV cure: Are we going to make history?

Altering cell death pathways as an approach to cure HIV infection